Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy JAZZ Stock  Free JAZZ Stock Alerts

Jazz Pharmaceuticals (JAZZ) Financials

Jazz Pharmaceuticals logo
$111.34 +0.33 (+0.29%)
As of 11:23 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Jazz Pharmaceuticals

Annual Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 560 415 -224 -330 239 523 447 488 397 330
Consolidated Net Income / (Loss)		 560 415 -224 -330 239 523 447 488 397 330
Net Income / (Loss) Continuing Operations		 560 415 -224 -330 239 523 447 488 397 330
Total Pre-Tax Income 		470 298 -373 -113 275 454 529 441 532 436
Total Operating Income		 717 579 -66 170 378 532 615 529 592 508
Total Gross Profit		 3,623 3,399 3,119 2,653 2,215 2,034 1,769 1,509 1,383 1,222
Total Revenue		 4,069 3,834 3,659 3,094 2,364 2,162 1,891 1,619 1,488 1,325
Operating Revenue		 4,069 3,834 3,659 3,094 2,364 2,162 1,891 1,619 1,488 1,325
Total Cost of Revenue		 446 436 541 441 149 128 122 110 105 103
Operating Cost of Revenue		 446 436 541 441 149 128 122 110 105 103
Total Operating Expenses		 2,907 2,820 3,184 2,483 1,837 1,501 1,155 980 791 714
Selling, General & Admin Expense		 1,385 1,343 1,417 1,452 854 737 684 544 503 449
Research & Development Expense		 894 869 1,035 506 587 410 227 283 186 135
Amortization Expense		 627 608 599 526 260 355 201 152 102 98
Impairment Charge		 0.00 0.00 134 0.00 136 0.00 43 0.00 0.00 32
Total Other Income / (Expense), net		 -246 -281 -307 -283 -103 -78 -85 -88 -59 -72
Interest & Investment Income		 -238 -289 -288 -279 -100 -72 -79 -78 -62 -57
Other Income / (Expense), net		 -8.18 8.79 -19 -4.35 -3.27 -5.81 -6.88 -9.97 3.37 1.45
Income Tax Expense		 -91 -120 -159 216 34 -73 80 -48 135 106
Other Gains / (Losses), net		 -1.66 -3.01 -9.92 -0.71 -2.96 -4.09 -2.20 -1.01 -0.38 0.00
Basic Earnings per Share		 $9.06 $6.55 ($3.58) ($5.52) $4.28 $9.22 $7.45 $8.13 $6.56 $5.38
Weighted Average Basic Shares Outstanding		 61.84M 63.29M 62.54M 59.69M 55.71M 56.75M 59.98M 60.02M 60.50M 61.23M
Diluted Earnings per Share		 $8.65 $6.10 ($3.58) ($5.52) $4.22 $9.09 $7.30 $7.96 $6.41 $5.23
Weighted Average Diluted Shares Outstanding		 66.01M 72.07M 62.54M 59.69M 56.52M 57.55M 61.22M 61.32M 61.87M 63.04M
Weighted Average Basic & Diluted Shares Outstanding		 60.73M 62.35M 63.33M 61.74M 56.33M 56.13M 60M 60M 60.50M 61.30M

Quarterly Income Statements for Jazz Pharmaceuticals

This table shows Jazz Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -93 191 215 169 -15 94 147 104 69 -241 -20
Consolidated Net Income / (Loss)		 -93 191 215 169 -15 94 147 104 69 -241 -20
Net Income / (Loss) Continuing Operations		 -93 191 215 169 -15 94 147 104 69 -241 -20
Total Pre-Tax Income 		-110 133 201 138 -1.60 62 100 82 55 -340 -60
Total Operating Income		 -56 191 260 199 66 122 172 158 126 -263 25
Total Gross Profit		 793 959 943 914 806 905 870 860 764 805 807
Total Revenue		 898 1,088 1,055 1,024 902 1,012 972 957 893 972 941
Operating Revenue		 898 1,088 1,055 1,024 902 1,012 972 957 893 972 941
Total Cost of Revenue		 105 129 112 110 95 107 102 98 129 167 134
Operating Cost of Revenue		 105 129 112 110 95 107 102 98 129 167 134
Total Operating Expenses		 849 769 683 714 740 782 698 702 638 1,068 782
Selling, General & Admin Expense		 514 369 326 339 352 396 308 341 298 383 358
Research & Development Expense		 181 241 200 221 233 235 234 209 190 548 149
Amortization Expense		 154 159 157 155 156 152 155 152 150 137 141
Total Other Income / (Expense), net		 -54 -58 -59 -62 -68 -61 -73 -76 -71 -77 -85
Interest & Investment Income		 -54 -51 -59 -62 -66 -70 -71 -73 -74 -74 -80
Other Income / (Expense), net		 -0.21 -6.30 -0.70 0.51 -1.69 9.35 -1.38 -2.38 3.19 -2.48 -4.65
Income Tax Expense		 -18 -58 -15 -31 12 -33 -47 -24 -15 -100 -43
Other Gains / (Losses), net		 -0.54 -0.02 -0.29 -0.01 -1.35 -0.46 0.13 -1.67 -1.01 -0.77 -2.55
Basic Earnings per Share		 ($1.52) $3.11 $3.50 $2.68 ($0.23) $1.50 $2.33 $1.63 $1.09 ($3.86) ($0.31)
Weighted Average Basic Shares Outstanding		 60.98M 61.84M 61.41M 62.88M 62.54M 63.29M 63.11M 63.99M 63.49M 62.54M 62.79M
Diluted Earnings per Share		 ($1.52) $2.97 $3.42 $2.49 ($0.23) $1.40 $2.14 $1.52 $1.04 ($3.85) ($0.31)
Weighted Average Diluted Shares Outstanding		 60.98M 66.01M 63.17M 69.63M 62.54M 72.07M 71.29M 73.54M 73.77M 62.54M 62.79M
Weighted Average Basic & Diluted Shares Outstanding		 61.63M 60.73M 60.45M 61.75M 63.04M 62.35M 62.96M 63.13M 64.00M 63.33M 62.97M

Annual Cash Flow Statements for Jazz Pharmaceuticals

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 907 625 290 -466 420 328 -75 20 -623 305
Net Cash From Operating Activities		 1,396 1,092 1,272 779 900 776 799 693 592 532
Net Cash From Continuing Operating Activities		 1,396 1,092 1,272 779 900 776 799 693 592 532
Net Income / (Loss) Continuing Operations		 560 415 -224 -330 239 523 447 488 397 330
Consolidated Net Income / (Loss)		 560 415 -224 -330 239 523 447 488 397 330
Depreciation Expense		 33 30 30 27 19 15 15 13 12 9.89
Amortization Expense		 627 608 599 526 260 355 245 182 124 121
Non-Cash Adjustments To Reconcile Net Income		 478 518 1,164 550 618 288 159 209 122 139
Changes in Operating Assets and Liabilities, net		 -302 -480 -297 5.66 -235 -405 -68 -199 -62 -67
Net Cash From Investing Activities		 -508 -163 -446 -5,212 -1,008 -155 -394 -269 -1,751 -2.26
Net Cash From Continuing Investing Activities		 -508 -163 -446 -5,212 -1,008 -155 -394 -269 -1,751 -2.26
Purchase of Property, Plant & Equipment		 -38 -24 -29 -28 -15 -40 -20 -29 -9.69 -36
Acquisitions		 -10 -19 -469 -6,253 -364 -197 -111 -85 -1,676 0.00
Purchase of Investments		 -1,305 -390 -61 -27 -2,398 -917 -1,166 -385 -132 0.00
Divestitures		 0.00 0.00 53 0.00 14 - - - - 34
Sale and/or Maturity of Investments		 845 270 60 1,095 1,755 985 855 230 67 0.00
Net Cash From Financing Activities		 21 -305 -529 3,971 528 -294 -479 -409 541 -214
Net Cash From Continuing Financing Activities		 21 -305 -529 3,971 528 -294 -479 -409 541 -214
Repayment of Debt		 -612 -31 -582 -1,321 -890 -33 -32 -886 -178 -1,066
Repurchase of Common Equity		 -311 -270 -0.05 0.00 -147 -301 -524 -99 -278 -62
Issuance of Debt		 981 0.00 0.00 5,191 1,481 0.00 0.00 559 995 899
Issuance of Common Equity		 21 46 98 135 100 58 93 32 24 41
Other Financing Activities, net		 -58 -51 -45 -36 -17 -17 -17 -15 -21 -26
Other Net Changes in Cash		 -1.68 - -6.22 -3.21 - - - 5.05 - -
Cash Interest Paid		 315 333 271 138 42 43 43 45 40 40
Cash Income Taxes Paid		 115 178 95 271 227 184 164 174 160 146

Quarterly Cash Flow Statements for Jazz Pharmaceuticals

This table details how cash moves in and out of Jazz Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -551 195 862 -88 -63 171 53 114 286 42 128
Net Cash From Operating Activities		 430 399 399 331 267 167 307 297 321 342 418
Net Cash From Continuing Operating Activities		 430 399 399 331 267 167 307 297 321 342 418
Net Income / (Loss) Continuing Operations		 -93 191 215 169 -15 94 147 104 69 -241 -20
Consolidated Net Income / (Loss)		 -93 191 215 169 -15 94 147 104 69 -241 -20
Depreciation Expense		 10 9.51 7.78 7.81 7.65 7.65 7.68 7.52 7.57 7.34 7.59
Amortization Expense		 154 159 157 155 156 152 155 152 150 137 141
Non-Cash Adjustments To Reconcile Net Income		 119 128 113 105 132 131 104 136 146 529 287
Changes in Operating Assets and Liabilities, net		 238 -89 -94 -105 -14 -217 -106 -104 -52 -91 1.42
Net Cash From Investing Activities		 -169 -193 214 -257 -272 102 -174 -86 -4.82 -324 4.60
Net Cash From Continuing Investing Activities		 -169 -193 214 -257 -272 102 -174 -86 -4.82 -324 4.60
Purchase of Property, Plant & Equipment		 -14 -13 -11 -7.09 -6.90 -10 -4.30 -5.74 -3.82 -9.38 4.90
Acquisitions		 -25 - - - -10 -18 - - -1.00 -375 -
Purchase of Investments		 -440 -470 -130 -330 -375 -120 -190 -80 0.00 - -0.30
Sale and/or Maturity of Investments		 310 290 355 80 120 250 20 - 0.00 60 -
Net Cash From Financing Activities		 -813 -8.28 246 -161 -57 -100 -78 -97 -30 20 -289
Net Cash From Continuing Financing Activities		 -813 -8.28 246 -161 -57 -100 -78 -97 -30 20 -289
Repayment of Debt		 -758 -13 -583 -7.75 -7.75 -7.75 -7.75 -7.75 -7.75 -7.75 -308
Issuance of Common Equity		 11 9.20 0.02 11 0.49 8.85 5.51 11 21 30 21
Other Financing Activities, net		 -67 -4.01 -1.61 -2.85 -49 -1.61 -1.88 -4.19 -43 -2.81 -2.57
Effect of Exchange Rate Changes		 1.70 - - - - - - - 0.33 - -

Annual Balance Sheets for Jazz Pharmaceuticals

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 12,012 11,393 10,835 12,299 6,536 5,539 5,203 5,124 4,800 3,333
Total Current Assets		 4,629 3,435 2,606 2,611 2,840 1,630 1,234 968 748 1,258
Cash & Equivalents		 2,413 1,506 881 591 1,058 637 310 386 366 989
Short-Term Investments		 580 120 0.00 - 1,075 440 515 215 60 0.00
Accounts Receivable		 717 706 651 563 396 356 264 224 234 210
Inventories, net		 480 597 714 1,073 95 79 53 43 34 19
Prepaid Expenses		 177 185 92 131 62 39 25 23 25 21
Other Current Assets		 262 321 267 252 152 79 68 77 29 19
Plant, Property, & Equipment, net		 173 170 228 257 128 132 200 170 107 86
Total Noncurrent Assets		 7,210 7,788 8,001 9,430 3,568 3,777 3,769 3,985 3,945 1,989
Goodwill		 1,716 1,753 1,693 1,828 958 920 928 948 894 657
Intangible Assets		 4,756 5,418 5,794 7,152 2,195 2,441 2,731 2,979 3,012 1,186
Noncurrent Deferred & Refundable Income Taxes		 560 478 376 311 255 221 58 35 15 130
Other Noncurrent Operating Assets		 168 133 128 127 155 187 43 16 14 9.27
Other Noncurrent Nonoperating Assets		 9.49 6.48 9.25 12 5.24 7.43 9.59 7.67 9.74 7.21
Total Liabilities & Shareholders' Equity		 12,012 11,393 10,835 12,299 6,536 5,539 5,203 5,124 4,800 3,333
Total Liabilities		 7,919 7,656 7,750 8,333 2,876 2,428 2,446 2,411 2,923 1,734
Total Current Liabilities		 1,039 1,537 933 809 654 364 345 294 257 227
Short-Term Debt		 31 605 31 31 246 33 33 41 36 38
Accounts Payable		 78 103 91 100 27 46 41 24 22 22
Accrued Expenses		 911 794 803 666 353 270 265 199 193 164
Current Deferred & Payable Income Tax Liabilities		 19 35 7.72 9.61 25 11 1.20 22 4.51 1.81
Total Noncurrent Liabilities		 6,880 6,120 6,816 7,524 2,222 2,063 2,101 2,117 2,665 1,507
Long-Term Debt		 6,078 5,108 5,693 6,019 1,849 1,574 1,563 1,540 1,994 1,151
Noncurrent Deferred & Payable Income Tax Liabilities		 677 848 944 1,301 130 224 309 383 557 283
Other Noncurrent Operating Liabilities		 126 164 179 204 241 261 219 177 113 69
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4,094 3,737 3,086 3,965 3,660 3,111 2,757 2,713 1,877 1,599
Total Preferred & Common Equity		 4,094 3,737 3,086 3,965 3,660 3,111 2,757 2,713 1,877 1,599
Total Common Equity		 4,094 3,737 3,086 3,965 3,660 3,111 2,757 2,713 1,877 1,599
Common Stock		 3,914 3,700 3,477 3,535 2,634 2,266 2,114 1,935 1,665 1,563
Retained Earnings		 1,127 879 734 830 1,160 1,068 841 918 529 303
Accumulated Other Comprehensive Income / (Loss)		 -948 -842 -1,126 -400 -134 -223 -198 -141 -317 -267
Other Equity Adjustments		 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53

Quarterly Balance Sheets for Jazz Pharmaceuticals

This table presents Jazz Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 11,535 12,256 11,362 11,327 11,204 11,261 11,047 10,385
Total Current Assets		 4,128 4,390 3,682 3,540 3,246 3,010 2,785 2,572
Cash & Equivalents		 1,862 2,218 1,356 1,443 1,336 1,282 1,168 839
Short-Term Investments		 710 400 625 375 250 80 - 60
Accounts Receivable		 653 724 698 707 628 610 624 601
Inventories, net		 493 539 543 577 612 657 675 728
Prepaid Expenses		 150 155 134 123 110 107 73 93
Other Current Assets		 260 354 326 315 310 272 245 250
Plant, Property, & Equipment, net		 179 176 169 166 222 229 228 216
Total Noncurrent Assets		 7,228 7,689 7,511 7,621 7,736 8,021 8,035 7,597
Goodwill		 1,760 1,805 1,736 1,739 1,705 1,743 1,723 1,593
Intangible Assets		 4,718 5,144 5,079 5,235 5,418 5,706 5,764 5,570
Noncurrent Deferred & Refundable Income Taxes		 575 583 545 508 464 430 399 315
Other Noncurrent Operating Assets		 166 152 145 132 141 135 140 109
Other Noncurrent Nonoperating Assets		 9.00 4.40 5.74 5.78 7.17 7.87 8.56 9.95
Total Liabilities & Shareholders' Equity		 11,535 12,256 11,362 11,327 11,204 11,261 11,047 10,385
Total Liabilities		 7,360 8,085 7,599 7,631 7,715 7,735 7,712 7,639
Total Current Liabilities		 1,223 1,030 1,556 1,562 1,573 945 909 813
Short-Term Debt		 31 31 606 605 605 31 31 31
Accounts Payable		 96 85 97 81 110 98 125 102
Accrued Expenses		 1,064 859 801 827 770 748 712 668
Current Deferred & Payable Income Tax Liabilities		 32 55 52 49 89 68 40 10
Total Noncurrent Liabilities		 6,137 7,055 6,043 6,068 6,141 6,790 6,803 6,827
Long-Term Debt		 5,336 6,081 5,101 5,105 5,111 5,687 5,690 5,696
Noncurrent Deferred & Payable Income Tax Liabilities		 671 792 775 810 841 911 932 934
Other Noncurrent Operating Liabilities		 130 182 167 154 189 192 181 197
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4,175 4,171 3,763 3,696 3,489 3,526 3,335 2,745
Total Preferred & Common Equity		 4,175 4,171 3,763 3,696 3,489 3,526 3,335 2,745
Total Common Equity		 4,175 4,171 3,763 3,696 3,489 3,526 3,335 2,745
Common Stock		 3,925 3,838 3,779 3,714 3,640 3,580 3,512 3,388
Retained Earnings		 1,035 936 871 864 884 812 803 974
Accumulated Other Comprehensive Income / (Loss)		 -786 -603 -888 -882 -1,035 -867 -980 -1,618
Other Equity Adjustments		 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.53

Annual Metrics And Ratios for Jazz Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 6.12% 4.78% 18.26% 30.91% 9.34% 14.32% 16.82% 8.79% 12.32% 12.95%
EBITDA Growth		 11.62% 125.00% -24.15% 10.01% -27.17% 3.23% 21.65% -2.31% 14.13% 82.12%
EBIT Growth		 20.61% 794.76% -150.95% -55.73% -28.82% -13.39% 17.17% -12.80% 16.75% 149.51%
NOPAT Growth		 5.48% 1,869.04% -138.48% -64.10% -46.29% 18.47% -10.98% 32.78% 14.89% 419.30%
Net Income Growth		 35.02% 285.14% 32.03% -238.16% -54.41% 17.06% -8.35% 22.94% 20.42% 474.84%
EPS Growth		 41.80% 270.39% 35.14% -230.81% -53.58% 24.52% -8.29% 24.18% 22.56% 462.37%
Operating Cash Flow Growth		 27.83% -14.15% 63.39% -13.47% 15.87% -2.82% 15.27% 17.00% 11.36% 30.50%
Free Cash Flow Firm Growth		 61.23% -36.84% 125.48% -1,726.79% -30.81% -26.66% 84.87% 130.02% -310.02% 182.64%
Invested Capital Growth		 -7.89% -1.29% -15.86% 160.24% -0.46% 3.23% -4.50% 6.17% 93.81% -10.30%
Revenue Q/Q Growth		 1.91% 1.05% 2.10% 8.08% 3.67% 5.12% 2.16% 2.52% 3.89% 0.97%
EBITDA Q/Q Growth		 4.73% 50.65% -37.68% -4.73% 6.79% -4.53% 4.48% 0.27% 9.83% -4.69%
EBIT Q/Q Growth		 8.02% 209.71% -137.56% -43.67% 43.36% -19.10% 7.61% -5.48% 11.57% -4.35%
NOPAT Q/Q Growth		 13.12% 501.57% -126.50% 119.13% 16.82% -10.94% -15.40% 34.42% 9.01% 0.08%
Net Income Q/Q Growth		 20.93% 418.84% -1,099.02% -104.89% 33.16% -14.04% -13.99% 31.03% 9.35% 0.35%
EPS Q/Q Growth		 22.18% 617.65% -867.57% -117.32% 33.54% -13.01% -13.71% 31.35% 9.95% -1.51%
Operating Cash Flow Q/Q Growth		 19.85% -13.79% 14.82% -1.08% 12.29% -14.37% 1.72% 3.57% 11.47% -2.66%
Free Cash Flow Firm Q/Q Growth		 108.02% 964.67% -32.49% 14.17% 8.19% -23.69% 4.49% 19.66% -2.89% -7.25%
Invested Capital Q/Q Growth		 -6.01% 2.70% 4.72% -1.27% 2.10% 1.48% -0.78% 2.70% 0.23% -3.41%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 89.05% 88.64% 85.23% 85.76% 93.70% 94.08% 93.57% 93.19% 92.92% 92.26%
EBITDA Margin		 33.63% 31.98% 14.89% 23.22% 27.63% 41.48% 45.94% 44.11% 49.12% 48.34%
Operating Margin		 17.61% 15.09% -1.79% 5.50% 16.00% 24.63% 32.52% 32.67% 39.76% 38.36%
EBIT Margin		 17.41% 15.32% -2.31% 5.36% 15.86% 24.36% 32.15% 32.06% 39.99% 38.47%
Profit (Net Income) Margin		 13.77% 10.82% -6.12% -10.65% 10.10% 24.21% 23.64% 30.14% 26.67% 24.87%
Tax Burden Percent		 119.09% 139.24% 60.10% 292.16% 86.74% 115.20% 84.44% 110.59% 74.53% 75.59%
Interest Burden Percent		 66.39% 50.72% 440.95% -68.00% 73.40% 86.28% 87.09% 85.01% 89.48% 85.53%
Effective Tax Rate		 -19.44% -40.25% 0.00% 0.00% 12.18% -16.10% 15.14% -10.82% 25.40% 24.41%
Return on Invested Capital (ROIC)		 11.40% 10.31% -0.53% 1.83% 9.16% 17.28% 14.48% 16.38% 16.78% 20.28%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.17% 1.41% -4.00% -14.78% -29.81% 2.53% 5.88% 8.72% 11.79% 6.92%
Return on Net Nonoperating Assets (RNNOA)		 2.91% 1.85% -5.83% -10.48% -2.11% 0.55% 1.86% 4.88% 6.06% 1.91%
Return on Equity (ROE)		 14.31% 12.16% -6.36% -8.65% 7.05% 17.84% 16.35% 21.26% 22.83% 22.19%
Cash Return on Invested Capital (CROIC)		 19.62% 11.61% 16.69% -87.13% 9.62% 14.10% 19.09% 10.39% -47.08% 31.14%
Operating Return on Assets (OROA)		 6.05% 5.28% -0.73% 1.76% 6.21% 9.80% 11.77% 10.46% 14.63% 15.28%
Return on Assets (ROA)		 4.79% 3.73% -1.94% -3.50% 3.95% 9.74% 8.66% 9.83% 9.76% 9.88%
Return on Common Equity (ROCE)		 14.31% 12.16% -6.36% -8.65% 7.05% 17.84% 16.35% 21.26% 22.83% 22.19%
Return on Equity Simple (ROE_SIMPLE)		 13.68% 11.10% -7.26% -8.31% 6.52% 16.82% 16.21% 17.98% 21.14% 20.61%
Net Operating Profit after Tax (NOPAT)		 856 811 -46 119 332 618 522 586 441 384
NOPAT Margin		 21.04% 21.16% -1.25% 3.85% 14.05% 28.59% 27.59% 36.21% 29.66% 29.00%
Net Nonoperating Expense Percent (NNEP)		 8.23% 8.90% 3.47% 16.61% 38.97% 14.75% 8.61% 7.66% 4.99% 13.36%
Return On Investment Capital (ROIC_SIMPLE)		 8.39% 8.59% -0.52% - - - - - - -
Cost of Revenue to Revenue		 10.95% 11.36% 14.77% 14.24% 6.30% 5.92% 6.43% 6.81% 7.08% 7.74%
SG&A Expenses to Revenue		 34.05% 35.03% 38.72% 46.92% 36.14% 34.09% 36.15% 33.62% 33.80% 33.90%
R&D to Revenue		 21.97% 22.66% 28.27% 16.34% 24.82% 18.95% 11.98% 17.51% 12.50% 10.21%
Operating Expenses to Revenue		 71.43% 73.55% 87.02% 80.25% 77.70% 69.46% 61.06% 60.52% 53.16% 53.90%
Earnings before Interest and Taxes (EBIT)		 708 587 -85 166 375 527 608 519 595 510
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1,369 1,226 545 718 653 897 869 714 731 640
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.82 2.07 3.25 1.98 2.51 2.71 2.71 2.98 3.48 5.41
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 18.16 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.83 2.02 2.74 2.53 3.89 3.91 3.95 4.99 4.39 6.52
Price to Earnings (P/E)		 13.29 18.67 0.00 0.00 38.54 16.14 16.72 16.55 16.46 26.23
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 7.52% 5.36% 0.00% 0.00% 2.59% 6.20% 5.98% 6.04% 6.08% 3.81%
Enterprise Value to Invested Capital (EV/IC)		 1.47 1.51 1.88 1.41 2.53 2.47 2.34 2.46 2.34 4.94
Enterprise Value to Revenue (EV/Rev)		 2.60 3.09 4.06 4.30 3.87 4.15 4.36 5.59 5.47 6.68
Enterprise Value to EBITDA (EV/EBITDA)		 7.72 9.65 27.30 18.50 14.02 10.01 9.50 12.68 11.13 13.81
Enterprise Value to EBIT (EV/EBIT)		 14.91 20.14 0.00 80.09 24.43 17.04 13.57 17.45 13.67 17.35
Enterprise Value to NOPAT (EV/NOPAT)		 12.34 14.58 0.00 111.50 27.58 14.52 15.81 15.45 18.43 23.02
Enterprise Value to Operating Cash Flow (EV/OCF)		 7.57 10.83 11.69 17.07 10.18 11.56 10.33 13.06 13.73 16.63
Enterprise Value to Free Cash Flow (EV/FCFF)		 7.17 12.95 10.28 0.00 26.25 17.80 12.00 24.34 0.00 14.99
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.49 1.53 1.86 1.53 0.57 0.52 0.58 0.58 1.08 0.74
Long-Term Debt to Equity		 1.48 1.37 1.85 1.52 0.51 0.51 0.57 0.57 1.06 0.72
Financial Leverage		 0.92 1.31 1.46 0.71 0.07 0.22 0.32 0.56 0.51 0.28
Leverage Ratio		 2.99 3.26 3.28 2.47 1.78 1.83 1.89 2.16 2.34 2.25
Compound Leverage Factor		 1.98 1.65 14.47 -1.68 1.31 1.58 1.64 1.84 2.09 1.92
Debt to Total Capital		 59.87% 60.45% 64.97% 60.41% 36.40% 34.06% 36.67% 36.82% 51.95% 42.64%
Short-Term Debt to Total Capital		 0.30% 6.40% 0.35% 0.31% 4.28% 0.71% 0.77% 0.95% 0.92% 1.35%
Long-Term Debt to Total Capital		 59.57% 54.05% 64.62% 60.10% 32.12% 33.36% 35.90% 35.87% 51.03% 41.29%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 40.13% 39.55% 35.03% 39.59% 63.60% 65.94% 63.33% 63.18% 48.05% 57.36%
Debt to EBITDA		 4.46 4.66 10.50 8.42 3.21 1.79 1.84 2.21 2.78 1.86
Net Debt to EBITDA		 2.28 3.33 8.89 7.60 -0.06 0.59 0.89 1.37 2.19 0.31
Long-Term Debt to EBITDA		 4.44 4.17 10.45 8.38 2.83 1.76 1.80 2.16 2.73 1.80
Debt to NOPAT		 7.14 7.04 -124.80 50.76 6.31 2.60 3.06 2.70 4.60 3.09
Net Debt to NOPAT		 3.64 5.04 -105.58 45.79 -0.11 0.86 1.48 1.67 3.63 0.52
Long-Term Debt to NOPAT		 7.10 6.29 -124.12 50.50 5.57 2.55 3.00 2.63 4.52 3.00
Altman Z-Score		 1.59 1.42 1.37 1.13 3.12 3.34 3.01 3.07 2.34 4.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 4.46 2.24 2.79 3.23 4.34 4.47 3.57 3.29 2.91 5.55
Quick Ratio		 3.57 1.52 1.64 1.43 3.87 3.93 3.15 2.81 2.56 5.29
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1,473 914 1,446 -5,676 349 504 688 372 -1,239 590
Operating Cash Flow to CapEx		 3,666.69% 4,557.24% 4,379.18% 2,816.49% 5,996.05% 2,994.68% 0.00% 2,394.08% 6,115.32% 1,479.35%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,941.67 35.08
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 928.51 31.64
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 913.33 29.50
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.35 0.35 0.32 0.33 0.39 0.40 0.37 0.33 0.37 0.40
Accounts Receivable Turnover		 5.72 5.65 6.02 6.45 6.28 6.98 7.75 7.06 6.70 6.69
Inventory Turnover		 0.83 0.66 0.61 0.75 1.71 1.94 2.53 2.85 3.94 4.14
Fixed Asset Turnover		 23.72 19.28 15.09 16.08 18.22 13.03 10.21 11.66 15.41 18.41
Accounts Payable Turnover		 4.94 4.50 5.66 6.93 4.10 2.96 3.74 4.71 4.77 4.37
Days Sales Outstanding (DSO)		 63.80 64.60 60.59 56.61 58.10 52.33 47.10 51.68 54.45 54.56
Days Inventory Outstanding (DIO)		 441.18 549.33 603.29 483.67 213.24 187.68 144.45 128.02 92.65 88.09
Days Payable Outstanding (DPO)		 73.96 81.08 64.51 52.69 89.07 123.16 97.55 77.48 76.58 83.54
Cash Conversion Cycle (CCC)		 431.03 532.86 599.37 487.59 182.28 116.85 93.99 102.22 70.52 59.11
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 7,200 7,817 7,919 9,412 3,617 3,633 3,520 3,685 3,471 1,791
Invested Capital Turnover		 0.54 0.49 0.42 0.48 0.65 0.60 0.52 0.45 0.57 0.70
Increase / (Decrease) in Invested Capital		 -617 -102 -1,492 5,795 -17 114 -166 214 1,680 -206
Enterprise Value (EV)		 10,561 11,830 14,874 13,290 9,158 8,975 8,249 9,052 8,134 8,844
Market Capitalization		 7,445 7,744 10,031 7,831 9,196 8,445 7,477 8,072 6,530 8,644
Book Value per Share		 $67.72 $59.36 $49.01 $64.51 $65.69 $54.99 $45.71 $45.26 $31.35 $26.00
Tangible Book Value per Share		 ($39.34) ($54.55) ($69.90) ($81.58) $9.09 ($4.42) ($14.95) ($20.24) ($33.87) ($3.97)
Total Capital		 10,202 9,450 8,810 10,015 5,755 4,718 4,354 4,294 3,907 2,787
Total Debt		 6,109 5,713 5,724 6,050 2,095 1,607 1,596 1,581 2,030 1,188
Total Long-Term Debt		 6,078 5,108 5,693 6,019 1,849 1,574 1,563 1,540 1,994 1,151
Net Debt		 3,116 4,087 4,843 5,458 -38 530 772 980 1,604 200
Capital Expenditures (CapEx)		 38 24 29 28 15 26 -28 29 9.69 36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 629 877 822 1,242 299 222 97 114 101 80
Debt-free Net Working Capital (DFNWC)		 3,621 2,504 1,704 1,833 2,432 1,299 922 715 527 1,069
Net Working Capital (NWC)		 3,590 1,899 1,673 1,802 2,186 1,266 889 674 491 1,031
Net Nonoperating Expense (NNE)		 296 397 178 449 93 95 75 98 45 55
Net Nonoperating Obligations (NNO)		 3,106 4,080 4,834 5,446 -43 522 762 972 1,594 192
Total Depreciation and Amortization (D&A)		 660 639 629 552 278 370 261 195 136 131
Debt-free, Cash-free Net Working Capital to Revenue		 15.45% 22.88% 22.48% 40.13% 12.67% 10.26% 5.14% 7.04% 6.77% 6.03%
Debt-free Net Working Capital to Revenue		 89.00% 65.30% 46.56% 59.24% 102.90% 60.10% 48.75% 44.17% 35.40% 80.66%
Net Working Capital to Revenue		 88.24% 49.52% 45.72% 58.24% 92.48% 58.55% 46.99% 41.66% 32.98% 77.82%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $9.06 $6.55 ($3.58) ($5.52) $4.28 $9.22 $7.45 $8.13 $6.56 $5.38
Adjusted Weighted Average Basic Shares Outstanding		 61.84M 63.29M 62.54M 59.69M 55.71M 56.75M 59.98M 60.02M 60.50M 61.23M
Adjusted Diluted Earnings per Share		 $8.65 $6.10 ($3.58) ($5.52) $4.22 $9.09 $7.30 $7.96 $6.41 $5.23
Adjusted Weighted Average Diluted Shares Outstanding		 66.01M 72.07M 62.54M 59.69M 56.52M 57.55M 61.22M 61.32M 61.87M 63.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.73M 62.35M 63.33M 61.74M 56.33M 56.13M 57.06M 59.80M 59.74M 61.18M
Normalized Net Operating Profit after Tax (NOPAT)		 502 405 48 119 452 373 558 370 441 408
Normalized NOPAT Margin		 12.33% 10.56% 1.30% 3.85% 19.11% 17.24% 29.52% 22.87% 29.66% 30.80%
Pre Tax Income Margin		 11.56% 7.77% -10.19% -3.65% 11.64% 21.02% 28.00% 27.25% 35.78% 32.91%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 932.64 30.31
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 691.82 22.85
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 917.46 28.17
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 676.63 20.71
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 55.60% 65.03% -0.02% 0.00% 61.41% 57.60% 117.13% 20.25% 70.13% 18.68%

Quarterly Metrics And Ratios for Jazz Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Jazz Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -0.46% 7.53% 8.52% 6.95% 1.03% 4.10% 3.35% 2.62% 9.72% 8.41% 12.23%
EBITDA Growth		 -52.27% 21.25% 27.33% 15.30% -20.48% 340.27% 97.45% 30.96% 11.64% -158.13% -12.61%
EBIT Growth		 -186.97% 39.91% 51.75% 28.79% -50.09% 149.59% 750.23% 84.38% 67.83% -707.45% -21.85%
NOPAT Growth		 -184.42% 45.29% 9.81% 19.19% -71.23% 202.17% 1,365.97% 35.32% 101.06% -633.39% -12.71%
Net Income Growth		 -533.06% 102.98% 46.48% 61.40% -121.06% 139.11% 847.25% 201.28% 4,114.94% -580.95% 62.81%
EPS Growth		 -560.87% 112.14% 59.81% 63.82% -122.12% 136.36% 790.32% 176.36% 3,366.67% -501.56% 63.95%
Operating Cash Flow Growth		 60.83% 138.19% 29.80% 11.65% -16.68% -51.07% -26.51% -2.07% 53.46% 92.38% 52.52%
Free Cash Flow Firm Growth		 69.84% 206.58% 12.41% -17.78% -74.05% -77.78% -89.68% -53.98% 124.03% 122.71% 133.28%
Invested Capital Growth		 -8.19% -7.89% 0.64% -4.96% -3.76% -1.29% 0.65% -6.71% -12.83% -15.86% -20.66%
Revenue Q/Q Growth		 -17.49% 3.15% 3.04% 13.51% -10.87% 4.09% 1.55% 7.22% -8.16% 3.35% 0.83%
EBITDA Q/Q Growth		 -69.18% -16.92% 17.01% 59.28% -21.70% -12.75% 5.95% 9.85% 336.60% -171.70% -29.73%
EBIT Q/Q Growth		 -130.41% -28.91% 29.79% 209.93% -51.07% -22.90% 10.15% 20.12% 148.61% -1,421.81% -76.11%
NOPAT Q/Q Growth		 -114.29% -1.91% 14.47% 425.99% -75.40% -25.87% 24.25% 26.94% 187.39% -1,163.63% -88.53%
Net Income Q/Q Growth		 -148.42% -11.13% 27.58% 1,253.15% -115.53% -35.87% 40.58% 50.44% 128.84% -1,125.18% -156.68%
EPS Q/Q Growth		 -151.18% -13.16% 37.35% 1,182.61% -116.43% -34.58% 40.79% 46.15% 127.01% -1,141.94% -156.36%
Operating Cash Flow Q/Q Growth		 7.83% -0.04% 20.34% 24.00% 59.69% -45.53% 3.51% -7.47% -6.22% -18.19% 37.93%
Free Cash Flow Firm Q/Q Growth		 -34.64% 286.50% -63.65% 84.97% 17.98% 41.71% -73.41% -41.62% 1.01% -34.17% 18.56%
Invested Capital Q/Q Growth		 -3.31% -6.01% 2.37% -1.32% -3.00% 2.70% -3.32% -0.08% -0.51% 4.72% -10.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.35% 88.17% 89.42% 89.27% 89.41% 89.40% 89.49% 89.81% 85.59% 82.78% 85.79%
EBITDA Margin		 12.11% 32.43% 40.26% 35.45% 25.27% 28.76% 34.31% 32.89% 32.10% -12.46% 17.96%
Operating Margin		 -6.23% 17.53% 24.67% 19.48% 7.34% 12.11% 17.73% 16.47% 14.12% -27.09% 2.63%
EBIT Margin		 -6.25% 16.95% 24.60% 19.53% 7.15% 13.03% 17.59% 16.22% 14.48% -27.35% 2.14%
Profit (Net Income) Margin		 -10.31% 17.56% 20.39% 16.46% -1.62% 9.30% 15.10% 10.91% 7.78% -24.76% -2.09%
Tax Burden Percent		 84.27% 143.46% 107.10% 122.22% 912.48% 153.03% 147.53% 127.70% 125.99% 70.80% 32.68%
Interest Burden Percent		 195.72% 72.22% 77.38% 68.98% -2.48% 46.66% 58.19% 52.68% 42.63% 127.88% -298.95%
Effective Tax Rate		 0.00% -43.47% -7.24% -22.22% 0.00% -53.78% -47.40% -29.74% -27.81% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -2.44% 13.63% 13.83% 12.12% 2.55% 9.07% 13.07% 9.86% 7.98% -8.01% 0.77%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.04% 11.33% 12.15% 10.26% 1.11% 6.96% 10.67% 7.77% 6.14% -9.11% 0.06%
Return on Net Nonoperating Assets (RNNOA)		 -3.42% 10.40% 12.07% 11.36% 1.33% 9.09% 15.30% 11.07% 8.82% -13.28% 0.10%
Return on Equity (ROE)		 -5.86% 24.03% 25.90% 23.48% 3.88% 18.16% 28.38% 20.93% 16.79% -21.28% 0.87%
Cash Return on Invested Capital (CROIC)		 19.45% 19.62% 9.27% 14.82% 13.13% 11.61% 1.13% 7.33% 13.49% 16.69% 25.07%
Operating Return on Assets (OROA)		 -2.22% 5.89% 8.37% 6.75% 2.46% 4.49% 6.18% 5.43% 4.74% -8.65% 0.67%
Return on Assets (ROA)		 -3.67% 6.11% 6.94% 5.69% -0.56% 3.21% 5.31% 3.66% 2.55% -7.83% -0.65%
Return on Common Equity (ROCE)		 -5.86% 24.03% 25.90% 23.48% 3.88% 18.16% 28.38% 20.93% 16.79% -21.28% 0.87%
Return on Equity Simple (ROE_SIMPLE)		 11.55% 0.00% 11.10% 10.50% 8.95% 0.00% 2.29% -2.45% -4.69% 0.00% -0.68%
Net Operating Profit after Tax (NOPAT)		 -39 274 279 244 46 188 254 205 161 -184 17
NOPAT Margin		 -4.36% 25.15% 26.45% 23.81% 5.14% 18.62% 26.14% 21.36% 18.05% -18.97% 1.84%
Net Nonoperating Expense Percent (NNEP)		 1.60% 2.30% 1.68% 1.86% 1.45% 2.11% 2.40% 2.09% 1.84% 1.10% 0.71%
Return On Investment Capital (ROIC_SIMPLE)		 -0.41% 2.68% - - - 1.99% - - - -2.09% -
Cost of Revenue to Revenue		 11.65% 11.83% 10.58% 10.73% 10.59% 10.60% 10.51% 10.19% 14.41% 17.22% 14.21%
SG&A Expenses to Revenue		 57.25% 33.94% 30.88% 33.06% 38.99% 39.14% 31.71% 35.60% 33.37% 39.42% 38.11%
R&D to Revenue		 20.12% 22.10% 18.95% 21.56% 25.82% 23.18% 24.11% 21.86% 21.33% 56.33% 15.83%
Operating Expenses to Revenue		 94.57% 70.64% 64.76% 69.79% 82.07% 77.30% 71.76% 73.35% 71.47% 109.88% 83.16%
Earnings before Interest and Taxes (EBIT)		 -56 184 260 200 65 132 171 155 129 -266 20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 109 353 425 363 228 291 334 315 287 -121 169
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.81 1.82 1.65 1.79 2.05 2.07 2.34 2.25 2.78 3.25 3.04
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.85 1.83 1.72 1.72 1.97 2.02 2.15 2.11 2.48 2.74 2.33
Price to Earnings (P/E)		 15.64 13.29 14.85 17.04 22.92 18.67 102.21 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 6.40% 7.52% 6.73% 5.87% 4.36% 5.36% 0.98% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.48 1.47 1.35 1.40 1.51 1.51 1.62 1.56 1.75 1.88 1.74
Enterprise Value to Revenue (EV/Rev)		 2.54 2.60 2.60 2.67 2.99 3.09 3.24 3.27 3.70 4.06 3.68
Enterprise Value to EBITDA (EV/EBITDA)		 8.27 7.72 7.94 8.60 9.83 9.65 15.12 18.93 24.04 27.30 15.07
Enterprise Value to EBIT (EV/EBIT)		 17.58 14.91 15.82 18.43 21.95 20.14 64.87 317.18 0.00 0.00 58.56
Enterprise Value to NOPAT (EV/NOPAT)		 13.03 12.34 13.71 13.98 15.97 14.58 91.20 389.57 0.00 0.00 76.17
Enterprise Value to Operating Cash Flow (EV/OCF)		 6.63 7.57 8.91 9.74 11.05 10.83 9.71 8.92 9.99 11.69 11.90
Enterprise Value to Free Cash Flow (EV/FCFF)		 7.31 7.17 14.65 9.19 11.30 12.95 143.35 20.54 12.11 10.28 6.15
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.29 1.49 1.47 1.52 1.54 1.53 1.64 1.62 1.72 1.86 2.09
Long-Term Debt to Equity		 1.28 1.48 1.46 1.36 1.38 1.37 1.46 1.61 1.71 1.85 2.07
Financial Leverage		 0.85 0.92 0.99 1.11 1.20 1.31 1.43 1.43 1.44 1.46 1.56
Leverage Ratio		 2.90 2.99 3.06 3.10 3.18 3.26 3.46 3.34 3.29 3.28 3.42
Compound Leverage Factor		 5.68 2.16 2.37 2.14 -0.08 1.52 2.02 1.76 1.40 4.20 -10.23
Debt to Total Capital		 56.25% 59.87% 59.44% 60.27% 60.71% 60.45% 62.09% 61.86% 63.17% 64.97% 67.60%
Short-Term Debt to Total Capital		 0.32% 0.30% 0.30% 6.40% 6.44% 6.40% 6.57% 0.34% 0.34% 0.35% 0.37%
Long-Term Debt to Total Capital		 55.92% 59.57% 59.14% 53.87% 54.27% 54.05% 55.52% 61.52% 62.83% 64.62% 67.23%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 43.75% 40.13% 40.56% 39.73% 39.30% 39.55% 37.91% 38.14% 36.83% 35.03% 32.40%
Debt to EBITDA		 4.30 4.46 4.68 4.70 4.89 4.66 7.02 8.81 9.95 10.50 6.55
Net Debt to EBITDA		 2.24 2.28 2.67 3.07 3.33 3.33 5.07 6.71 7.92 8.89 5.52
Long-Term Debt to EBITDA		 4.27 4.44 4.65 4.20 4.37 4.17 6.28 8.76 9.90 10.45 6.51
Debt to NOPAT		 6.77 7.14 8.08 7.63 7.95 7.04 42.37 181.24 -302.43 -124.80 33.09
Net Debt to NOPAT		 3.53 3.64 4.62 4.98 5.42 5.04 30.61 138.06 -240.69 -105.58 27.89
Long-Term Debt to NOPAT		 6.73 7.10 8.04 6.82 7.10 6.29 37.89 180.26 -300.80 -124.12 32.91
Altman Z-Score		 1.38 1.44 1.34 1.27 1.27 1.29 1.31 1.32 1.40 1.31 1.34
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.38 4.46 4.26 2.37 2.27 2.24 2.06 3.18 3.06 2.79 3.16
Quick Ratio		 2.64 3.57 3.24 1.72 1.62 1.52 1.41 2.09 1.97 1.64 1.85
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 582 891 230 634 343 291 205 771 1,321 1,308 1,987
Operating Cash Flow to CapEx		 3,096.20% 2,999.77% 3,696.21% 4,672.85% 3,870.64% 1,656.49% 7,145.73% 5,171.02% 8,391.10% 3,646.52% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.36 0.35 0.34 0.35 0.34 0.35 0.35 0.34 0.33 0.32 0.31
Accounts Receivable Turnover		 5.98 5.72 5.91 5.98 5.78 5.65 6.17 6.25 6.25 6.02 6.52
Inventory Turnover		 0.85 0.83 0.74 0.69 0.64 0.66 0.74 0.69 0.67 0.61 0.55
Fixed Asset Turnover		 23.56 23.72 20.02 19.62 19.52 19.28 17.29 16.05 15.41 15.09 0.00
Accounts Payable Turnover		 5.14 4.94 4.35 4.24 3.90 4.50 4.67 6.11 5.57 5.66 6.13
Days Sales Outstanding (DSO)		 61.06 63.80 61.77 61.07 63.20 64.60 59.11 58.41 58.40 60.59 56.02
Days Inventory Outstanding (DIO)		 429.36 441.18 495.19 527.88 567.83 549.33 493.31 525.80 547.04 603.29 668.62
Days Payable Outstanding (DPO)		 70.98 73.96 84.00 86.03 93.62 81.08 78.09 59.74 65.50 64.51 59.51
Cash Conversion Cycle (CCC)		 419.44 431.03 472.96 502.93 537.42 532.86 474.33 524.47 539.94 599.37 665.14
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6,961 7,200 7,660 7,483 7,583 7,817 7,612 7,873 7,879 7,919 7,563
Invested Capital Turnover		 0.56 0.54 0.52 0.51 0.50 0.49 0.50 0.46 0.44 0.42 0.42
Increase / (Decrease) in Invested Capital		 -621 -617 49 -390 -296 -102 49 -567 -1,160 -1,492 -1,970
Enterprise Value (EV)		 10,335 10,561 10,374 10,454 11,473 11,830 12,302 12,290 13,820 14,874 13,182
Market Capitalization		 7,540 7,445 6,880 6,728 7,581 7,744 8,172 7,935 9,267 10,031 8,355
Book Value per Share		 $68.74 $67.72 $67.54 $59.69 $59.11 $59.36 $55.27 $55.08 $52.66 $49.01 $43.80
Tangible Book Value per Share		 ($37.93) ($39.34) ($44.98) ($48.43) ($52.43) ($54.55) ($57.56) ($61.29) ($65.57) ($69.90) ($70.48)
Total Capital		 9,542 10,202 10,283 9,469 9,407 9,450 9,205 9,243 9,056 8,810 8,472
Total Debt		 5,367 6,109 6,112 5,707 5,710 5,713 5,715 5,718 5,721 5,724 5,727
Total Long-Term Debt		 5,336 6,078 6,081 5,101 5,105 5,108 5,111 5,687 5,690 5,693 5,696
Net Debt		 2,796 3,116 3,494 3,726 3,892 4,087 4,130 4,355 4,553 4,843 4,827
Capital Expenditures (CapEx)		 14 13 11 7.09 6.90 10 4.30 5.74 3.82 9.38 -4.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 364 629 773 751 765 877 691 733 739 822 890
Debt-free Net Working Capital (DFNWC)		 2,936 3,621 3,391 2,731 2,583 2,504 2,277 2,096 1,907 1,704 1,790
Net Working Capital (NWC)		 2,905 3,590 3,360 2,126 1,978 1,899 1,672 2,065 1,876 1,673 1,759
Net Nonoperating Expense (NNE)		 53 83 64 75 61 94 107 100 92 56 37
Net Nonoperating Obligations (NNO)		 2,787 3,106 3,489 3,720 3,886 4,080 4,122 4,347 4,544 4,834 4,818
Total Depreciation and Amortization (D&A)		 165 168 165 163 163 159 163 160 157 145 149
Debt-free, Cash-free Net Working Capital to Revenue		 8.96% 15.45% 19.37% 19.20% 19.90% 22.88% 18.22% 19.49% 19.76% 22.48% 24.84%
Debt-free Net Working Capital to Revenue		 72.23% 89.00% 84.94% 69.86% 67.21% 65.30% 60.01% 55.69% 51.00% 46.56% 49.93%
Net Working Capital to Revenue		 71.47% 88.24% 84.16% 54.37% 51.46% 49.52% 44.08% 54.87% 50.17% 45.72% 49.07%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.52) $3.11 $3.50 $2.68 ($0.23) $1.50 $2.33 $1.63 $1.09 ($3.86) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 60.98M 61.84M 61.41M 62.88M 62.54M 63.29M 63.11M 63.99M 63.49M 62.54M 62.79M
Adjusted Diluted Earnings per Share		 ($1.52) $2.97 $3.42 $2.49 ($0.23) $1.40 $2.14 $1.52 $1.04 ($3.85) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 60.98M 66.01M 63.17M 69.63M 62.54M 72.07M 71.29M 73.54M 73.77M 62.54M 62.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.63M 60.73M 60.45M 61.75M 63.04M 62.35M 62.96M 63.13M 64.00M 63.33M 62.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 134 182 140 46 86 121 110 88 -184 111
Normalized NOPAT Margin		 -4.36% 12.27% 17.27% 13.64% 5.14% 8.47% 12.41% 11.53% 9.88% -18.97% 11.79%
Pre Tax Income Margin		 -12.23% 12.24% 19.03% 13.47% -0.18% 6.08% 10.24% 8.54% 6.17% -34.97% -6.39%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 55.60% 88.79% 84.98% 0.00% 65.03% 212.58% -110.50% 0.00% -0.02% -0.29%

Frequently Asked Questions About Jazz Pharmaceuticals' Financials

When does Jazz Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Jazz Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Jazz Pharmaceuticals' net income changed over the last 9 years?

Jazz Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $560.12 million in 2024, rising from $329.53 million in 2015. The previous period was $414.83 million in 2023. See where experts think Jazz Pharmaceuticals is headed by visiting Jazz Pharmaceuticals' forecast page.

What is Jazz Pharmaceuticals's operating income?
Jazz Pharmaceuticals's total operating income in 2024 was $716.63 million, based on the following breakdown:
  • Total Gross Profit: $3.62 billion
  • Total Operating Expenses: $2.91 billion
How has Jazz Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Jazz Pharmaceuticals' total revenue changed from $1.32 billion in 2015 to $4.07 billion in 2024, a change of 207.1%.

How much debt does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals' total liabilities were at $7.92 billion at the end of 2024, a 3.4% increase from 2023, and a 356.7% increase since 2015.

How much cash does Jazz Pharmaceuticals have?

In the past 9 years, Jazz Pharmaceuticals' cash and equivalents has ranged from $309.62 million in 2018 to $2.41 billion in 2024, and is currently $2.41 billion as of their latest financial filing in 2024.

How has Jazz Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Jazz Pharmaceuticals' book value per share changed from 26.00 in 2015 to 67.72 in 2024, a change of 160.5%.


Related Companies

This page (NASDAQ:JAZZ) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored